MYRIAD GENETICS, INC.

PositionAround Utah

Salt Lake City -- MYRIAD GENETICS, INC. announced that AstraZeneca will use Myriad's myChoice HRD Plus in an exploratory analysis to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza (olaparib) and Avastin (bevacizumab).Under the...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT